Immunome Inc. (IMNM) · Oct 5, 2026 · Acquisition
$20M patent purchase — $20M cash plus 4,425,487 shares for transferred patents
Immunome’s acquisition from BMS gives it direct patent ownership around its lead program, but requires $20 million and 4.4 million shares.
Immunome is moving from a single lead asset toward a broader oncology company: varegacestat is nearing a potential FDA decision for desmoid tumors, while IM-1021, IM-1617, IM-3050 and newer ADCs expand the pipeline. This amendment mainly strengthens control over the legacy BMS-licensed asset rather than adding a new drug or new clinical data.
Immunome is buying cleaner, longer-term control of the BMS patent estate. BMS will transfer specified patent rights to Immunome, and the agreement now runs by product and country until the last applicable transferred patent expires. 〔0〕 〔1〕 That removes dependence on BMS to maintain, prosecute and enforce those patents and appears to replace much of the previous milestone, royalty-reporting and development-obligation framework with a direct ownership structure.
| Consideration | Amount | Filing location |
|---|---|---|
| Cash payment to BMS | $20.0 million | (Cash Payment) |
| Immunome shares issued to BMS | 4,425,487 | (Stock Issuance) |
| BMS research license | Perpetual, worldwide, fully paid, non-exclusive | (Transferred Patents) |
The strategic cleanup is not free. Immunome pays $20 million immediately and issues 4.4 million shares; the cash payment is about 3.8% of the $520 million in cash, cash equivalents and marketable securities reported at June 30, 2026. 〔2〕 〔3〕 The cash cost is manageable against the stated runway, but the equity issuance adds dilution before varegacestat has generated any commercial revenue.
The deal improves asset control more than asset value. Nothing in this filing changes varegacestat’s clinical efficacy, regulatory status or approval odds; it changes who owns and administers key intellectual property and reduces contractual friction around future development and commercialization. BMS still receives broad rights to use the transferred patents for molecules outside the licensed compounds and products, so Immunome is not receiving unrestricted control over every possible use of the patent estate. 〔4〕
Bottom line: This is a meaningful ownership and licensing simplification around Immunome’s lead program, funded with a modest cash outlay but real shareholder dilution. It advances execution certainty, not the underlying clinical or regulatory case.
Varegacestat PDUFA decision, April 28, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.